The company was born in the laboratory, as part of the R&D department of Sequentia Biotech. Led by Dr. Luis Matías Hernández, it was set up to research and optimize different plants that produce various medicinal and aromatic compounds in their trichomes, starting with Artemisia annua. Continuing the positive results obtained in laboratory and field studies, in October 2018, Biotech Tricopharming Research was founded with the objective of continuing the development and commercialization of improved Artemisia annua, known as Artennua.
In parallel, the company is applying its technology to other medicinal and aromatic plants, such as lavender, thyme, mint and basil, among others. In addition to continuing the development of its R&D, Biotech Tricopharming Research also offers customized R&D services and field trials to other companies and research centers that are interested in improving the commercial production of plants for the pharmaceutical and nutraceutical sectors. and cosmetic.
- ACTIVITY: Biotechnology to improve the therapeutic potential of various medicinal plants.
- LOCATION: Barcelona.
- CONSTITUTION DATE: 10/2018.
- CATEGORY: small agropharma/plant biotechnology company.
- CONTACT: (+34) 695 124 590.
- NUMBER OF EMPLOYEES: 5.
- INCOME: -
- GENERAL DESCRIPTION: Biotech Tricopharming Research SL is a biotechnology start-up founded in 2018 after several years of R&D. Our general mission is to create the know-how and technologies necessary to increase the therapeutic potential of different medicinal and aromatic plants (MAPs). The Biopharmaceutical agriculture either Biopharming It combines biotechnology and agriculture to produce valuable pharmacological products in plants but at a reduced cost. In our first product, Artennua®, we increase the production of various compounds of interest in the plant Artemisia annua; a plant used to combat malaria, cancer, as well as other diseases in both humans and animals
- BUSINESS LINES: Sale of Artennua® for nutraceutical, natural cosmetics and animal health sectors. License to use our technology TricoStimulant™ for different MAPs plants.
- INFRASTRUCTURE: Headquarters in Barcelona. Operational, production and experimental headquarters in Tenerife.
- DATA OF INTEREST: Although created in 2018, R&D was developed in-house Sequentia Biotech SL from 2015 to 2018.
TECHNOLOGICAL SUPPLY/DEMAND:
- We offer consultancy and customized R&D projects to companies or research centers to increase the therapeutic potential of different MAPs.
- We develop biostimulants tailored.
- We search collaborations with other companies and/or research centers to new R&D projects.
- We search collaborations with other companies and/or research centers to study stability and new formats for different biostimulants.
DEVELOPMENT PROJECTS
- Platform production of therapeutic molecules in plants. CDTI.
COMPLETED PROJECTS
- Biotechnology for production of the molecule artemisinin in the trichomes of the plant Artemisia annua. Validation of technology TricoStimulant™ on field. MINECO-CDTI.
English 
Spanish